RAS/RAF/MEK inhibitors in oncology

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The RAS/RAF/MEK signaling pathway is a key regulator of cell proliferation and survival.
• Dysregulation of this pathway, often due to RAS/B-RAF mutations, is implicated in over 30% of human cancers.
• Pathway alterations can lead to drug resistance, particularly in tumors with K-RAS mutations.

Purpose of the Study:

• To review promising strategies for targeting B-RAF and MEK kinases in cancer therapy.
• To discuss recent preclinical and clinical inhibitors, including their structure-activity relationships (SAR).
• To explore alternative approaches like farnesyl transferase inhibitors for targeting RAS.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of structure-activity relationships for novel kinase inhibitors.
• Discussion of drug resistance mechanisms and therapeutic strategies.

Main Results:

• Hyperactivation of MEK1/2 typically arises from RAS/B-RAF mutations, not MEK1/2 gene mutations.
• Targeting B-RAF and MEK has become a major focus for drug discovery programs.
• Several promising inhibitors are advancing through preclinical and clinical development.

Conclusions:

• Targeting the RAS/RAF/MEK pathway offers significant therapeutic potential in oncology.
• Understanding SAR is crucial for developing effective and selective inhibitors.
• Addressing drug resistance mechanisms is essential for long-term treatment success.